Genetic diversity of EBV-encoded LMP1 in the swiss HIV cohort study and implication for NF-κb activation

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Zuercher, Emilie ^a   Butticaz, Christophe ^a   Wyniger, Josiane ^a   Martinez, Raquel ^a   Battegay, Manuel ^b   El Amari, Emmanuelle Boffi ^c   Dang, Thanh ^a   Egger, Jean François ^d   Fehr, Jan ^e   Mueller Garamvögyi, Esther ^f   Parini, Andrea ^g   Schaefer, Stephan C ^h   Schoeni Affolter, Franziska ^a   Thurnheer, Christine ^f   Tinguely, Marianne ⁱ   Telenti, Amalio ^a   Rothenberger, Sylvia ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Pathology Laboratoire Viollier Weintraub SA   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; PROTEIN VARIANT; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC GROUP; GENETIC VARIABILITY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN POLYMORPHISM; SIGNAL TRANSDUCTION; SWISS; TRANSCRIPTION INITIATION; TUMOR BIOPSY; BIOLOGICAL MODEL; CELL SURVIVAL; EPSTEIN BARR VIRUS; GENETIC POLYMORPHISM; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; METABOLISM; MUTATION; PHYLOGENY; POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS CELL TRANSFORMATION;

HUMAN HERPESVIRUS 4;

CELL SURVIVAL; CELL TRANSFORMATION, VIRAL; DNA MUTATIONAL ANALYSIS; GENETIC VARIATION; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HUMANS; LYMPHOCYTES; MODELS, BIOLOGICAL; MUTATION; NF-KAPPA B; PHYLOGENY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; VIRAL MATRIX PROTEINS;

EID: 84857499396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032168     Document Type: Article

References (60)

1. Young LS, Rickinson AB, (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
2. Kilger E, Kieser A, Baumann M, Hammerschmidt W, (1998) Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. Embo J 17: 1700-1709.
3. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, et al. (2003) Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus. Cancer Res 63: 2982-2989.
4. Kaye KM, Izumi KM, Kieff E, (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90: 9150-9154.
5. Wang D, Liebowitz D, Kieff E, (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43: 831-840.
6. Baichwal VR, Sugden B, (1988) Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2: 461-467.
7. Dawson CW, Rickinson AB, Young LS, (1990) Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344: 777-780.
8. Hammarskjold ML, Simurda MC, (1992) Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol 66: 6496-6501.
9. Mitchell T, Sugden B, (1995) Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 69: 2968-2976.
10. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E, (2000) NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A 97: 6055-6060.
11. Hoffmann A, Baltimore D, (2006) Circuitry of nuclear factor kappaB signaling. Immunol Rev 210: 171-186.
12. Perkins ND, Gilmore TD, (2006) Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 13: 759-772.
13. Keller SA, Hernandez-Hopkins D, Vider J, Ponomarev V, Hyjek E, et al. (2006) NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 107: 3295-3302.
14. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, et al. (1991) Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72 (Pt 10): 2399-2409.
15. Blake SM, Eliopoulos AG, Dawson CW, Young LS, (2001) The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology 282: 278-287.
16. Johnson RJ, Stack M, Hazlewood SA, Jones M, Blackmore CG, et al. (1998) The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. J Virol 72: 4038-4048.
17. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF, (2009) HIV-associated lymphomas and gamma-herpesviruses. Blood 113: 1213-1224.
18. Gasser O, Bihl FK, Wolbers M, Loggi E, Steffen I, et al. (2007) HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS medicine 4: e96.
19. Spina M, Carbone A, Gloghini A, Serraino D, Berretta M, et al. (2011) Hodgkin's Disease in Patients with HIV Infection. Adv Hematol 2011.
20. Dolcetti R, Boiocchi M, Gloghini A, Carbone A, (2001) Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer 37: 1276-1287.
21. Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, et al. (2009) Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 113: 5737-5742.
22. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, et al. (2005) Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97: 425-432.
23. Young LS, Murray PG, (2003) Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22: 5108-5121.
24. Fennewald S, van Santen V, Kieff E, (1984) Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 51: 411-419.
25. Rothenberger S, Rousseaux M, Knecht H, Bender FC, Legler DF, et al. (2002) Association of the Epstein-Barr virus latent membrane protein 1 with lipid rafts is mediated through its N-terminal region. Cell Mol Life Sci 59: 171-180.
26. Graham FL, Smiley J, Russell WC, Nairn R, (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
27. Nicholls J, Hahn P, Kremmer E, Frohlich T, Arnold GJ, et al. (2004) Detection of wild type and deleted latent membrane protein 1 (LMP1) of Epstein-Barr virus in clinical biopsy material. J Virol Methods 116: 79-88.
28. Telenti A, Uehlinger DE, Marchesi F, Germann D, Malinverni R, et al. (1993) Epstein-Barr virus infection in HIV-positive patients. Eur J Clin Microbiol Infect Dis 12: 601-609.
29. Edwards RH, Sitki-Green D, Moore DT, Raab-Traub N, (2004) Potential selection of LMP1 variants in nasopharyngeal carcinoma. J Virol 78: 868-881.
30. Dolcetti R, Zancai P, De Re V, Gloghini A, Bigoni B, et al. (1997) Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood 89: 1723-1731.
31. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, et al. (1993) Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82: 2937-2942.
32. Knecht H, Bachmann E, Brousset P, Rothenberger S, Einsele H, et al. (1995) Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 10: 523-528.
33. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K, (2009) The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus research 143: 209-221.
34. Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N, (1999) Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 261: 79-95.
35. Walling DM, Shebib N, Weaver SC, Nichols CM, Flaitz CM, et al. (1999) The molecular epidemiology and evolution of Epstein-Barr virus: sequence variation and genetic recombination in the latent membrane protein-1 gene. J Infect Dis 179: 763-774.
36. Sandvej K, Gratama JW, Munch M, Zhou XG, Bolhuis RL, et al. (1997) Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: identification of four variants among wild-type EBV isolates. Blood 90: 323-330.
37. Fielding CA, Sandvej K, Mehl A, Brennan P, Jones M, et al. (2001) Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J Virol 75: 9129-9141.
38. Mainou BA, Raab-Traub N, (2006) LMP1 strain variants: biological and molecular properties. J Virol 80: 6458-6468.
39. Miller WE, Cheshire JL, Baldwin AS Jr, Raab-Traub N, (1998) The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells. Oncogene 16: 1869-1877.
40. Nguyen-Van D, Ernberg I, Phan-Thi Phi P, Tran-Thi C, Hu L, (2008) Epstein-Barr virus genetic variation in Vietnamese patients with nasopharyngeal carcinoma: full-length analysis of LMP1. Virus Genes 37: 273-281.
41. Tang YL, Lu JH, Cao L, Wu MH, Peng SP, et al. (2008) Genetic variations of EBV-LMP1 from nasopharyngeal carcinoma biopsies: potential loss of T cell epitopes. Braz J Med Biol Res 41: 110-116.
42. Nagamine M, Takahara M, Kishibe K, Nagato T, Ishii H, et al. (2007) Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma. Virus Genes 34: 47-54.
43. Cheung ST, Leung SF, Lo KW, Chiu KW, Tam JS, et al. (1998) Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong. Int J Cancer 76: 399-406.
44. Jen KY, Higuchi M, Cheng J, Li J, Wu LY, et al. (2005) Nucleotide sequences and functions of the Epstein-Barr virus latent membrane protein 1 genes isolated from salivary gland lymphoepithelial carcinomas. Virus Genes 30: 223-235.
45. Sample J, Young L, Martin B, Chatman T, Kieff E, et al. (1990) Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64: 4084-4092.
46. Hu LF, Chen F, Zheng X, Ernberg I, Cao SL, et al. (1993) Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 8: 1575-1583.
47. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, et al. (2006) Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108: 3786-3791.
48. Tirelli U, Serraino D, Spina M, Carbone A, (1995) Epstein-Barr virus-encoded latent membrane protein-1 expression as prognostic factor in AIDS-related non-Hodgkin's lymphoma. AIDS 9: 99-100.
49. Carbone A, Gloghini A, Larocca LM, Antinori A, Falini B, et al. (1999) Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 93: 2319-2326.
50. Rezk SA, Weiss LM, (2007) Epstein-Barr virus-associated lymphoproliferative disorders. Human pathology 38: 1293-1304.
51. Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, et al. (2004) Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. Journal of virology 78: 4108-4119.
52. Izumi KM, Kaye KM, Kieff ED, (1997) The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America 94: 1447-1452.
53. He Z, Xin B, Yang X, Chan C, Cao L, (2000) Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts. Cancer research 60: 1845-1848.
54. Baud V, Karin M, (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40.
55. Kuppers R, (2009) Molecular biology of Hodgkin lymphoma. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program pp. 491-496.
56. Schmitz R, Stanelle J, Hansmann ML, Kuppers R, (2009) Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annual review of pathology 4: 151-174.
57. Farrell K, Jarrett RF, (2011) The molecular pathogenesis of Hodgkin lymphoma. Histopathology 58: 15-25.
58. Correa RM, Fellner MD, Durand K, Redini L, Alonio V, et al. (2007) Epstein Barr virus genotypes and LMP-1 variants in HIV-infected patients. J Med Virol 79: 401-407.
59. Faumont N, Al Saati T, Brousset P, Offer C, Delsol G, et al. (2001) Demonstration by single-cell PCR that Reed-Sternberg cells and bystander B lymphocytes are infected by different Epstein-Barr virus strains in Hodgkin's disease. The Journal of general virology 82: 1169-1174.
60. Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, et al. (2010) Cohort profile: the Swiss HIV Cohort study. International journal of epidemiology 39: 1179-1189.